This article is more than 5 years old. Information may no longer be current.
Alcon launches trifocal toric IOL in Europe
Click Here to Manage Email Alerts
Alcon has launched a new toric IOL to treat both astigmatism and presbyopia, parent company Novartis announced in a press release.
The trifocal AcrySof IQ PanOptix Toric IOL, which was given CE mark in November 2016, is “intended for primary implantation in the capsular bag of the posterior chamber of the human eye for the visual correction of aphakia and pre-existing corneal astigmatism secondary to removal of a cataractous lens or clear lens,” according to the release.
The lens, which combines the trifocal optic of the AcrySof IQ PanOptix IOL on the front with toric astigmatic correction on the back and provides an intermediate focal point at 60 cm, is indicated for patients with and without presbyopia who seek greater spectacle independence, according to the release.
“The launch of the AcrySof IQ PanOptix Toric intraocular lens is a significant step forward in Alcon’s presbyopia-correcting portfolio and extends our reach into the presbyopic population,” Alcon CEO and Division Head Mike Ball said in the release.
The lens has been introduced in markets in Spain, Portugal and Chile.